مركز الكويت لمكافحة السرطان
Kuwait Cancer Control Center

PACLItaxel / Ramucirumab (RAINBOW Trial)

PCLRMC-OO-O4-CN-GI

Ministry of Health

Name: **File #:** **Ht (cm):**
Nationality: **Civil ID:** **Wt (Kg):**
Gender/Age: **DOB:** **BSA (m²):**

Indication(s): Gastric and gastro-oesophageal junction adenocarcinoma, advanced or metastatic.
Central line: ☐ Available ☐ NA **Allergies:** ☐ NKA ☐ Yes, specify; _____

Parameters: Initiate treatment only if ANC ≥ 1000; HB ≥ 80; Plt ≥ 100,000; CrCl > 45 ml/min.

Pre-treatment Medications: (30-60 min before starting treatment)

Ondansetron	8 mg PO/IV
Dexamethasone	10 mg PO/IV
Chlorphenamine	10 mg PO/IV

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
Ramucirumab	8 mg/kg	IV in 250 mL NS over 60 min.	D1, 15
PACLItaxel	80 mg/m²	IV in 500 mL D5W glass bottle over 60 min.	D1, 8, 15
To be repeated every 4 weeks until disease progression or intolerable toxicity.			

Treatment Description:

Cycle	Day	Date	Ramucirumab	PACLItaxel	Physician	Consultant
C# __	D1					
	D8		XXXXXXX			
	D15					

Cycle	Day	Date	Ramucirumab	PACLItaxel	Physician	Consultant
C# __	D1					
	D8		XXXXXXX			
	D15					

Important Notes:

Reported grade 3/4 toxicities: ☐ None ☐ Hematological ☐ Non-Hematological

If yes; Did it indicate hospitalization? ☐ Yes ☐ No
Did it indicate chemo-delay for ≥ 7 days? ☐ Yes ☐ No
Did it indicate dose reduction? ☐ Yes ☐ No
Did it indicate G-CSF support? ☐ Yes ☐ No